These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15540238)

  • 1. Acceptance of tamoxifen chemoprevention by physicians and women at risk.
    McKay A; Latosinsky S; Martin W
    Cancer; 2005 Jan; 103(1):209-10. PubMed ID: 15540238
    [No Abstract]   [Full Text] [Related]  

  • 2. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.
    Bober SL; Hoke LA; Duda RB; Regan MM; Tung NM
    J Clin Oncol; 2004 Dec; 22(24):4951-7. PubMed ID: 15598980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acceptance of tamoxifen chemoprevention by physicians and women at risk.
    Tchou J; Hou N; Rademaker A; Jordan VC; Morrow M
    Cancer; 2004 May; 100(9):1800-6. PubMed ID: 15112259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current status of breast cancer chemoprevention: a star is born.
    Morrow M; Jordan VC
    J Surg Oncol; 2007 Jan; 95(1):4-5. PubMed ID: 17192883
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemoprevention Indication Score: a user-friendly tool for prevention of breast cancer - pilot analysis.
    Layeequr Rahman R; Crawford S
    Breast; 2009 Oct; 18(5):289-93. PubMed ID: 19716702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoprevention of breast cancer: recommendations and rationale.
    Am Fam Physician; 2003 Mar; 67(6):1309-14. PubMed ID: 12674459
    [No Abstract]   [Full Text] [Related]  

  • 7. Women's decision making about whether or not to use breast cancer chemoprevention.
    Altschuler A; Somkin CP
    Women Health; 2005; 41(2):81-95. PubMed ID: 16219589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprevention of breast cancer for women at high risk.
    Chan K; Morris GJ
    Semin Oncol; 2006 Dec; 33(6):642-6. PubMed ID: 17145342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
    Melnikow J; Paterniti D; Azari R; Kuenneth C; Birch S; Kuppermann M; Nuovo J; Keyzer J; Henderson S
    Cancer; 2005 May; 103(10):1996-2005. PubMed ID: 15825209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point.
    Jordan VC
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2207-9. PubMed ID: 18006908
    [No Abstract]   [Full Text] [Related]  

  • 11. Keeping breast cancer at bay. Women at risk are asked to weigh the pros and cons of a prevention pill.
    Brink S
    US News World Rep; 1999 May; 126(21):76. PubMed ID: 10387894
    [No Abstract]   [Full Text] [Related]  

  • 12. Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users.
    Rondanina G; Puntoni M; Severi G; Varricchio C; Zunino A; Feroce I; Bonanni B; Decensi A
    J Clin Oncol; 2008 Mar; 26(9):1537-43. PubMed ID: 18349406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
    Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
    Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen chemoprevention and cardiac disease.
    Narod SA; Iqbal J
    J Clin Oncol; 2011 Aug; 29(22):3106-7; author reply 3107. PubMed ID: 21709203
    [No Abstract]   [Full Text] [Related]  

  • 15. Tamoxifen: an enduring star.
    Veronesi U; Maisonneuve P; Decensi A
    J Natl Cancer Inst; 2007 Feb; 99(4):258-60. PubMed ID: 17312297
    [No Abstract]   [Full Text] [Related]  

  • 16. Tamoxifen (TAM): the dispute goes on.
    Grilli S
    Ann Ist Super Sanita; 2006; 42(2):170-3. PubMed ID: 17033137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen and breast cancer prevention: what should you tell your patients?
    Goel V
    CMAJ; 1998 Jun; 158(12):1615-7. PubMed ID: 9645176
    [No Abstract]   [Full Text] [Related]  

  • 18. Breast cancer risk assessment and risk reduction.
    Newman LA; Vogel VG
    Surg Clin North Am; 2007 Apr; 87(2):307-16, vii-viii. PubMed ID: 17498528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
    J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myxoid leiomyosarcoma of the uterus in a patient receiving tamoxifen therapy: a case report.
    Botsis D; Koliopoulos C; Kondi-Pafitis A; Creatsas G
    Int J Gynecol Pathol; 2006 Apr; 25(2):173-5. PubMed ID: 16633068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.